Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IHL-675A in Patients With Rheumatoid Arthritis
NCT05942911Phase 2Terminated
- Sponsor
- Incannex Healthcare
- Start
- Nov 2023
- Primary completion
- Oct 2024
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of IHL-675A in rheumatoid arthritis (RA) (4 arms), sponsored by Incannex Healthcare. Primary endpoint: Routine Assessment of Patient Index Data 3 at 24 weeks. Started Nov 2023; status: terminated.
02
Drugs
IHL-675A
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT05942911.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05942911.